Jade Biosciences, Inc. Financing Cash Flow
Jade Biosciences, Inc. (JBIO) reported Financing Cash Flow of $192.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- Jade Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $193.52M, a 1.16% increase year-over-year.
- Jade Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$795.00K.
- Jade Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $170.16M.
- Jade Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Jade Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $360.77M, a 1318.84% increase from fiscal 2024.
- Jade Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $25.43M, a 44.72% decline from fiscal 2023.
- Jade Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $46.00M, a 11515.15% increase from fiscal 2022.
- Jade Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $396.00K, a 99.79% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 0 month | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $193.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $192.73M 10-Q · filed 2026-08-10 | $362.89M derived: sum of 3 quarters · filed 2026-08-10 | $362.89M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | -$795.00K 10-Q · filed 2026-05-07 | $169.37M derived: sum of 2 quarters · filed 2026-05-07 | $169.37M derived: sum of 3 quarters · filed 2026-05-07 | $360.67M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $170.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $170.16M derived: sum of 2 quarters · filed 2026-03-06 | $361.47M derived: sum of 3 quarters · filed 2026-08-10 | $360.77M 10-K · filed 2026-03-06 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $191.31M derived: sum of 2 quarters · filed 2026-08-10 | $190.61M 10-Q · filed 2025-11-14 | $187.84M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $191.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $190.61M 10-Q · filed 2026-08-10 | $187.84M derived: sum of 3 quarters · filed 2026-08-10 | $282.61M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | -$700.00K 10-Q · filed 2026-05-07 | -$3.47M derived: sum of 2 quarters · filed 2026-05-07 | $91.30M derived: sum of 3 quarters · filed 2026-05-07 | $115.68M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$2.77M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | $92.00M 10-K · filed 2026-03-06 | $116.38M derived: sum of 3 quarters · filed 2026-03-06 | $25.43M 10-K · filed 2025-03-27 | |
| 2024-09-30 | $94.77M 10-Q · filed 2025-11-14 | $119.15M derived: sum of 2 quarters · filed 2025-11-14 | $24.87M 10-Q · filed 2024-11-12 | $120.09M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | $24.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $24.85M 10-Q · filed 2024-08-12 | $25.31M derived: sum of 3 quarters · filed 2025-04-25 | $25.33M derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-03-31 | $471.00K 10-Q · filed 2025-04-25 | $934.00K derived: sum of 2 quarters · filed 2025-04-25 | $954.00K derived: sum of 3 quarters · filed 2025-04-25 | $46.24M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2023-12-31 | $463.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $483.00K derived: sum of 2 quarters · filed 2025-03-27 | $45.77M derived: sum of 3 quarters · filed 2025-03-27 | $46.00M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $45.31M derived: sum of 2 quarters · filed 2024-11-12 | $45.53M 10-Q · filed 2024-11-12 | $45.89M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $45.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $45.51M 10-Q · filed 2024-08-12 | $45.87M derived: sum of 3 quarters · filed 2024-08-12 | $45.91M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $223.00K 10-Q · filed 2024-05-13 | $580.00K derived: sum of 2 quarters · filed 2024-05-13 | $617.00K derived: sum of 3 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $394.00K derived: sum of 2 quarters · filed 2024-03-25 | $396.00K 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $39.00K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $2.00K 10-Q · filed 2023-08-14 | ||||
| 2021-12-31 | -$250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $128.06M derived: sum of 2 quarters · filed 2023-03-29 | $182.57M derived: sum of 3 quarters · filed 2023-03-29 | $190.46M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $128.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $182.82M derived: sum of 2 quarters · filed 2022-11-14 | $190.71M 10-Q · filed 2022-11-14 | $190.71M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $54.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $62.40M 10-Q · filed 2022-08-15 | $62.40M derived: sum of 3 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $7.88M 10-Q · filed 2022-05-16 | $7.88M derived: sum of 2 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $8.92M 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $8.92M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |